Efectividad y seguridad del efavirenz combinado con tenofovir y emtricitabina para el tratamiento de pacientes mayores de 13 años de edad con infección por VIH, que no han recibido terapia anti-retroviral

Everth, Arlene; Díaz, Miguel; Vanegas, Egdda; Mejía, Aurelio; Moreno, Mabel; Osorio, Diana Isabel; Moreno, Ornella; Sussman, Otto; Álvarez, Néstor; Barrios Vidales, Mauricio.
Bogotá; Observatorio Medicamentos de Alto Impacto Financiero; 2015. [159] p.
No convencional en Español | BRISA | ID: biblio-847179

Documentos relacionados

  1. Anti-HIV Drugs Cause Mitochondrial Dysfunction in Monocyte-Derived Macrophages.
  2. An Investigation of Liquid Chromatography-Mass Spectral Attributes and Analytical Performance Characteristics of Tenofovir, Emtricitabine and Efavirenz in Human Plasma.
  3. A maintenance 3-day-per-week schedule with the single tablet regimen efavirenz/emtricitabine/tenofovir disoproxil fumarate is effective and decreases sub-clinical toxicity.
  4. Effects on immune system and viral reservoir of a short-cycle antiretroviral therapy in virologically suppressed HIV-positive patients.
  5. Human Immunodeficiency Virus Type 1 Vpu Inhibitor, BIT225, in Combination with 3-Drug Antiretroviral Therapy: Inflammation and Immune Cell Modulation.
  6. Coadministration of ARV (Atripla) and Topiramate disrupts quail cardiac neural crest cell migration.
  7. Patient-reported outcomes in the single-tablet regimen (STaR) trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate in antiretroviral treatment-naive adults infected with HIV-1 through 48 weeks of treatment.
  8. Untimed Efavirenz Drug Levels After Switching From Brand to Generic Formulations: A Short Communication.
  9. Acute Kidney Injury After Efavirenz/Tenofovir Disoproxil Fumarate/Emtricitabine (Atripla) Overdose.
  10. WITHDRAWN. Effectiveness and safety of first-line tenofovir + emtricitabine + efavirenz for patients with HIV.